Drug intelligence / Profile preview

interferon beta + interleukin-2

Development stage: Discontinued
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

A combination immunotherapy consisting of interferon beta (IFN-beta) and interleukin-2 (IL-2). Both are biological response modifiers that work through different but complementary immune pathways. When combined, they appear to have synergistic antitumor effects that were initially demonstrated in mouse tumor models[4]. This synergy provided the rationale for human clinical trials. The combination has been primarily investigated for renal cell carcinoma and other advanced malignancies, though clinical results have shown modest efficacy with response rates around 9-10%.

Other names: IFN-beta + IL-2

Targets

IFNAR (Immune system modulation via type I interferon receptor)IL-2R (Interleukin-2/interleukin-15 receptor complex)

Beyond the preview

Go deeper on interferon beta + interleukin-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on interferon beta + interleukin-2.

Explore the full profile